本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Ventyx Biosciences, Inc.

2.08
+0.03501.72%
成交量:13.59万
成交额:28.10万
市值:1.48亿
市盈率:-1.18
高:2.09
开:2.05
低:2.04
收:2.04
数据加载中...
2023/05/11

重要事件披露

8-K - Current report
2023/05/11

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/05/05

关联方拟减持公告

144 - Report of proposed sale of securities
2023/05/03

关联方拟减持公告

144 - Report of proposed sale of securities
2023/05/03

关联方拟减持公告

144 - Report of proposed sale of securities
2023/04/28

关联方拟减持公告

144 - Report of proposed sale of securities
2023/04/07

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/03/23

重要事件披露

8-K - Current report
2023/03/23

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/03/22

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/03/02

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/01/30

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/01/26

重要事件披露

8-K - Current report
2023/01/12

重要事件披露

8-K - Current report
2023/01/05

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2022/12/30

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/20

重要事件披露

8-K - Current report
2022/12/16

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/15

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership